Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong. more
Time Frame | HCM | Sector | S&P500 |
---|---|---|---|
1-Week Return | -8.68% | -2.28% | -0.57% |
1-Month Return | -8.57% | -3.98% | 1.2% |
3-Month Return | -9.89% | -9.71% | 7.56% |
6-Month Return | -16.42% | -3.39% | 11.44% |
1-Year Return | -19.81% | 3.69% | 28.47% |
3-Year Return | -52.67% | 3.78% | 29.51% |
5-Year Return | -32.38% | 39.76% | 90.64% |
10-Year Return | 16.27% | 106.88% | 203.73% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 204.89M | 227.98M | 356.13M | 426.41M | 838.00M | [{"date":"2019-12-31","value":24.45,"profit":true},{"date":"2020-12-31","value":27.2,"profit":true},{"date":"2021-12-31","value":42.5,"profit":true},{"date":"2022-12-31","value":50.88,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 160.15M | 188.52M | 258.23M | 311.10M | 384.45M | [{"date":"2019-12-31","value":41.66,"profit":true},{"date":"2020-12-31","value":49.04,"profit":true},{"date":"2021-12-31","value":67.17,"profit":true},{"date":"2022-12-31","value":80.92,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 44.74M | 39.46M | 97.89M | 115.31M | 453.55M | [{"date":"2019-12-31","value":9.86,"profit":true},{"date":"2020-12-31","value":8.7,"profit":true},{"date":"2021-12-31","value":21.58,"profit":true},{"date":"2022-12-31","value":25.42,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 21.84% | 17.31% | 27.49% | 27.04% | 54.12% | [{"date":"2019-12-31","value":40.34,"profit":true},{"date":"2020-12-31","value":31.98,"profit":true},{"date":"2021-12-31","value":50.79,"profit":true},{"date":"2022-12-31","value":49.96,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 189.76M | 236.13M | 426.21M | 523.00M | 436.23M | [{"date":"2019-12-31","value":36.28,"profit":true},{"date":"2020-12-31","value":45.15,"profit":true},{"date":"2021-12-31","value":81.49,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.41,"profit":true}] |
Operating Income | (145.02M) | (188.95M) | (336.46M) | (409.77M) | 18.38M | [{"date":"2019-12-31","value":-789.22,"profit":false},{"date":"2020-12-31","value":-1028.28,"profit":false},{"date":"2021-12-31","value":-1831.06,"profit":false},{"date":"2022-12-31","value":-2230.04,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Total Non-Operating Income/Expense | 7.83M | 9.38M | 114.06M | 6.22M | 75.32M | [{"date":"2019-12-31","value":6.86,"profit":true},{"date":"2020-12-31","value":8.23,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":5.45,"profit":true},{"date":"2023-12-31","value":66.03,"profit":true}] |
Pre-Tax Income | (141.10M) | (189.73M) | (215.74M) | (410.42M) | 58.31M | [{"date":"2019-12-31","value":-242,"profit":false},{"date":"2020-12-31","value":-325.4,"profit":false},{"date":"2021-12-31","value":-370,"profit":false},{"date":"2022-12-31","value":-703.89,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income Taxes | 3.27M | 4.83M | 11.92M | (283.00K) | 4.51M | [{"date":"2019-12-31","value":27.47,"profit":true},{"date":"2020-12-31","value":40.52,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-2.37,"profit":false},{"date":"2023-12-31","value":37.83,"profit":true}] |
Income After Taxes | (144.38M) | (194.56M) | (227.66M) | (410.14M) | 53.80M | [{"date":"2019-12-31","value":-268.37,"profit":false},{"date":"2020-12-31","value":-361.65,"profit":false},{"date":"2021-12-31","value":-423.16,"profit":false},{"date":"2022-12-31","value":-762.35,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Continuous Operations | (103.68M) | (115.52M) | (167.04M) | (360.39M) | 101.09M | [{"date":"2019-12-31","value":-102.56,"profit":false},{"date":"2020-12-31","value":-114.27,"profit":false},{"date":"2021-12-31","value":-165.23,"profit":false},{"date":"2022-12-31","value":-356.49,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (144.38M) | (194.56M) | (227.66M) | (410.14M) | 100.78M | [{"date":"2019-12-31","value":-143.26,"profit":false},{"date":"2020-12-31","value":-193.06,"profit":false},{"date":"2021-12-31","value":-225.9,"profit":false},{"date":"2022-12-31","value":-406.96,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
EPS (Diluted) | (0.69) | (0.96) | (0.97) | (2.68) | 0.97 | [{"date":"2019-12-31","value":-70.94,"profit":false},{"date":"2020-12-31","value":-98.68,"profit":false},{"date":"2021-12-31","value":-99.6,"profit":false},{"date":"2022-12-31","value":-276.29,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
HCM | |
---|---|
Cash Ratio | 2.15 |
Current Ratio | 2.81 |
Quick Ratio | 2.68 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
HCM | |
---|---|
ROA (LTM) | -5.90% |
ROE (LTM) | -5.44% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
HCM | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.40 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.59 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
HCM | |
---|---|
Trailing PE | NM |
Forward PE | 83.33 |
P/S (TTM) | 4.48 |
P/B | 3.60 |
Price/FCF | NM |
EV/R | 4.65 |
EV/Ebitda | 36.81 |
PEG | NM |
HUTCHMED DRC (HCM) share price today is $15.105
Yes, Indians can buy shares of HUTCHMED DRC (HCM) on Vested. To buy HUTCHMED DRC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in HCM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of HUTCHMED DRC (HCM) via the Vested app. You can start investing in HUTCHMED DRC (HCM) with a minimum investment of $1.
You can invest in shares of HUTCHMED DRC (HCM) via Vested in three simple steps:
The 52-week high price of HUTCHMED DRC (HCM) is $21.92. The 52-week low price of HUTCHMED DRC (HCM) is $11.93.
The price-to-earnings (P/E) ratio of HUTCHMED DRC (HCM) is
The price-to-book (P/B) ratio of HUTCHMED DRC (HCM) is 3.60
The dividend yield of HUTCHMED DRC (HCM) is 0.00%
The market capitalization of HUTCHMED DRC (HCM) is $2.74B
The stock symbol (or ticker) of HUTCHMED DRC is HCM